Formycon AG

2 marketed · 1 in Phase 3

Quick facts

Marketed products

AHZANTIVE · Other
NUFYMCO · Other

Phase 3 pipeline

FYB206 · Ophthalmology
FYB206 is a biosimilar of aflibercept (Eylea) that inhibits vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to reduce abnormal blood vessel growth in the eye.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: